Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05636540 · ClinicalTrials.gov registry record · Early Phase 1
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
A Early Phase 1 study of Pheochromocytoma and Paraganglioma, sponsored by Heather Wachtel.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05636540 is a Early Phase 1 study of Pheochromocytoma and Paraganglioma that is actively recruiting participants, run by Heather Wachtel. The registered enrollment target is 30 participants, below the 518-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05636540, a Early Phase 1 study of Pheochromocytoma and Paraganglioma, is actively recruiting participants, sponsored by Heather Wachtel.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will enroll up to 30 evaluable patients with pheochromocytoma or paraganglioma who are undergoing surgical or systemic treatment. A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy. PET/CT imaging will be used to evaluate PARP-1 expression in sites of pheochromocytoma or paraganglioma using the investigational radiotracer \[18F\]FTT. This is an observational study in that \[18F\]FTT PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the \[18F\]FTT PET/CT results, treatment decisions will be made by the treating physicians based upon clinical criteria.
Conditions Studied
Interventions
- DRUG [18F]FluorThanatrace ([18F]FTT)
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05636540
The ClinicalTrials.gov registry entry for NCT05636540 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 518-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (94% lower). The listed sponsor is Heather Wachtel, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pheochromocytoma appearing as the primary indexed condition, and to 1 intervention - of which [18F]FluorThanatrace ([18F]FTT) is the first listed.
NCT05636540 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05636540 about?
NCT05636540 is a clinical study titled "In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma". This study will enroll up to 30 evaluable patients with pheochromocytoma or paraganglioma who are undergoing surgical or systemic treatment. A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic ther...
What is the current status of trial NCT05636540?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2023-07-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05636540 study?
This clinical trial studies the following conditions: Pheochromocytoma, Paraganglioma.
What interventions are being tested in trial NCT05636540?
The interventions under investigation include: [18F]FluorThanatrace ([18F]FTT) (DRUG).
Who is sponsoring clinical trial NCT05636540?
This trial is sponsored by Heather Wachtel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05636540 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pheochromocytoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
RECRUITING · Phase 1
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Diagnosis of Pheochromocytoma
RECRUITING · Phase 1
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.